Astellas Pharma Inc. (ALPMY)

Astellas Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	188,372	335,687	376,840	315,986	326,128
Cash & Short-Term Investments	188,372	335,687	376,840	315,986	326,128
Cash Growth	-43.89%	-10.92%	19.26%	-3.11%	2.43%
Accounts Receivable	632,525	534,985	427,965	382,462	343,178
Other Receivables	13,691	13,051	17,813	21,539	13,984
Receivables	646,216	548,036	445,778	404,001	357,162
Inventory	297,261	248,738	174,386	153,072	164,080
Other Current Assets	69,500	62,269	52,950	50,295	25,218
Total Current Assets	1,201,349	1,194,730	1,049,954	923,354	872,588
Property, Plant & Equipment	328,921	293,742	286,459	269,044	264,623
Long-Term Investments	18,989	163,018	145,028	141,206	146,804
Goodwill	415,207	418,694	328,411	303,030	284,011
Other Intangible Assets	1,123,714	1,453,824	562,496	623,431	651,427
Long-Term Accounts Receivable	18,453	-	-	-	-
Long-Term Deferred Tax Assets	98,113	45,594	84,169	72,331	54,176
Other Long-Term Assets	134,798	1	1	-1	-1
Total Assets	3,339,544	3,569,603	2,456,518	2,332,395	2,273,628
Accounts Payable	187,840	185,193	140,236	130,739	124,777
Accrued Expenses	-	155,233	143,817	136,553	124,898
Short-Term Debt	-	420,393	75,000	90,000	120,000
Current Portion of Long-Term Debt	266,533	51,885	-	50,000	-
Current Portion of Leases	-	14,944	13,546	17,730	16,101
Current Income Taxes Payable	34,549	38,515	5,137	32,388	8,395
Other Current Liabilities	572,688	419,562	348,298	230,001	198,201
Total Current Liabilities	1,061,610	1,285,725	726,034	687,411	592,372
Long-Term Debt	564,893	449,937	54,217	676	80,400
Long-Term Leases	-	70,756	61,461	55,014	62,163
Long-Term Deferred Tax Liabilities	5,353	51,346	6,048	5,823	18,161
Other Long-Term Liabilities	171,687	91,177	75,986	85,937	95,435
Total Liabilities	1,826,289	1,973,615	948,564	872,087	887,513
Common Stock	103,001	103,001	103,001	103,001	103,001
Additional Paid-In Capital	185,259	184,070	181,280	179,467	177,830
Retained Earnings	740,939	809,400	908,158	944,261	953,289
Treasury Stock	-37,524	-33,783	-25,123	-13,934	-15,377
Comprehensive Income & Other	521,580	533,300	340,638	247,513	167,372
Shareholders' Equity	1,513,255	1,595,988	1,507,954	1,460,308	1,386,115
Total Liabilities & Equity	3,339,544	3,569,603	2,456,518	2,332,395	2,273,628
Total Debt	831,426	1,007,915	204,224	213,420	278,664
Net Cash (Debt)	-643,054	-672,228	172,616	102,566	47,464
Net Cash Growth	-	-	68.30%	116.09%	-
Net Cash Per Share	-357.82	-373.53	94.58	55.42	25.54
Filing Date Shares Outstanding	1,790	1,793	1,797	1,827	1,853
Total Common Shares Outstanding	1,790	1,793	1,797	1,827	1,853
Working Capital	139,739	-90,995	323,920	235,943	280,216
Book Value Per Share	845.21	890.07	839.26	799.26	748.03
Tangible Book Value	-25,666	-276,530	617,047	533,847	450,677
Tangible Book Value Per Share	-14.34	-154.22	343.42	292.19	243.21

Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.